Adjuvant and neoadjuvant therapy for pancreatic cancer
Authors:
Open Access
- 23 July 2019
- journal article
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 2 (3) , 100-106
Abstract
Pancreatic cancer still remains a major cause of cancer-related mortality; however, there is a slight but continuous improvement in survival over the past 2 decades. Progress in chemotherapy has contributed to the survival improvement in patients with any stage of pancreatic cancer. In this review, we summarize the currently available evidence regarding adjuvant and neoadjuvant therapy with a focus mainly on randomized controlled trial. The median overall survival in resected pancreatic cancer patients has significantly improved to 22.8 to 54.4 months with the use of adjuvant therapy from 11 to 20.2 months with a strategy of observation only. Recent data from randomized trials support the use of neoadjuvant therapy for patients with resectable or borderline resectable pancreatic cancer. But given a variety of neoadjuvant regimens and different definitions of resectability status, data should be interpreted with caution. Several other trials are ongoing and will provide further evidence.Keywords
This publication has 48 references indexed in Scilit:
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or ObservationAnnals of Surgery, 2007
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary RegionAnnals of Surgery, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Pancreatic CancerArchives of Surgery, 1985